ArticleDiabetes2019
Central and Peripheral Administration of Fibroblast Growth Factor 1 Improves Pancreatic Islet Insulin Secretion in Diabetic Mouse Models.
Article in Diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Engineered Brain-Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.Molecular biomedicine · 2026Article
- A key role for parabrachial nucleus CGRP neurons in FGF1-Induced anorexia.Molecular metabolism · 2025Article
- FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025Review
- Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance.Frontiers in endocrinology · 2023Article
- The fibroblast growth factor system in cognitive disorders and dementia.Frontiers in neuroscience · 2023Review
- Autocrine FGF1 signaling promotes glucose uptake in adipocytes.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Sustained inhibition of NPY/AgRP neuronal activity by FGF1.JCI insight · 2022Article
- Metabolic Messengers: fibroblast growth factor 1.Nature metabolism · 2022Review
- The ventromedial hypothalamic nucleus: watchdog of whole-body glucose homeostasis.Cell & bioscience · 2022Review
- Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?Annual review of pharmacology and toxicology · 2022Review
- Role of hypothalamic MAPK/ERK signaling and central action of FGF1 in diabetes remission.iScience · 2021Article
- Article
- Central nervous system regulation of organismal energy and glucose homeostasis.Nature metabolism · 2021Review
- Brain control of blood glucose levels: implications for the pathogenesis of type 2 diabetes.Diabetologia · 2021Review
- Fibroblast Growth Factor-1 Activates Neurons in the Arcuate Nucleus and Dorsal Vagal Complex.Frontiers in endocrinology · 2021Article
- NmFGF1-Regulated Glucolipid Metabolism and Angiogenesis Improves Functional Recovery in a Mouse Model of Diabetic Stroke and ActsFrontiers in pharmacology · 2021Article
- Leptin modulates pancreatic β-cell membrane potential through Src kinase-mediated phosphorylation of NMDA receptors.The Journal of biological chemistry · 2020Article
- Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission.Nature communications · 2020Article
- Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice.Psychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Fibroblast growth factor 1 (FGF1) has been shown to reverse hyperglycemia in diabetic rodent models through peripheral and central administration routes. Previous studies demonstrated that insulin is required for central and peripheral FGF1 metabolic improvements; however, it is unknown if FGF1 targets insulin secretion at the islet level. Here we show for the first time that FGF1 increases islet insulin secretion in diabetic mouse models. FGF1 was administered via a single intracerebroventricular or multiple subcutaneous injections to leptin receptor-deficient (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.